Julie D Saba
- University of California, San Francisco · Pediatrics (NIH department code)
- Sphinxion Therapeutics, Inc (no department on record)
- Gordon Research Conferences (no department on record)
From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.
FY2026 NIH rank #10,832
- R01 Holder
- Multi-Institutional
- Early Career
- Diverse Portfolio
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 1866596Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award categories
- Pediatrics
NIH Funding · FY2026
Linked Award Amount
$1.9M
Full award amounts, FY2026
Award Records
6
Records listing this PI
Award-Linked Rank
#10,832
By linked amount among FY2026 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2026 award records by amount
NIH award records listing Julie D Saba as a PI. Multi-PI records show the full award amount for context.
- 5R01HD113778-03R01Contact PICharacterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosisUniversity of California, San Francisco · Pediatrics (NIH department code)$671.9Kaward amount
- 4R33HL171786-03R33Contact PIAdeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signalingUniversity of California, San Francisco · Pediatrics (NIH department code)$574Kaward amount
- 1R42DK148319-01R42Contact PIAAV-SPL, a one-time gene therapy for rare and common forms of fibrotic kidney disease$352.2Kaward amount
- 5R21OD037868-02R21Contact PICharacterizing a novel mouse model linking sphingolipid metabolism to multi-organ fibrosisUniversity of California, San Francisco · Pediatrics (NIH department code)$205Kaward amount
- 3R01HD113778-03S1R01Contact PICharacterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosisUniversity of California, San Francisco · Pediatrics (NIH department code)$50Kaward amount
- 1R13HD122430-01R13Contact PI2026 Glycolipid and Sphingolipid Biology Gordon Research Conference and Gordon Research Seminar$20Kaward amount
Award organizations
Organizations that administered FY2026 awards listing Julie D Saba as a PI.
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardUniversity of California, San Francisco
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #6968
- 2025$2M Cumulative Funding
- 2025Multi-Institutional ResearchAwards at 3 institutions
- 2025R01 Grant Holder
- 2026$5M Cumulative Funding
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Julie D Saba.